Online inquiry

IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15020MR)

This product GTTS-WQ15020MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CSF1R gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001288705.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1436
UniProt ID P07333
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ15020MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4414MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-663513
GTTS-WQ13766MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-1033
GTTS-WQ2533MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 477
GTTS-WQ8797MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IBI-308
GTTS-WQ2413MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 145
GTTS-WQ14248MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RG-7116
GTTS-WQ4647MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-986036
GTTS-WQ10063MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA L19-IL-2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW